Delving Into Participation Trends in Renal Cell Carcinoma Studies
Study Details
Study Description
Brief Summary
The study seeks to delve into the firsthand experiences of patients diagnosed with renal cell carcinoma who partake in a separate clinical study featuring a specific medical intervention. The primary emphasis will be on meticulously tracking the rates of trial completion and withdrawal among these individuals.
By joining this clinical trial, individuals have the unique opportunity to contribute to the betterment of future renal cell carcinoma patients and play an active role in advancing clinical research.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Study Design
Outcome Measures
Primary Outcome Measures
- Number of patients who decide to participate in a renal cell carcinoma clinical study [3 months]
- Rate of patients who remain in renal cell carcinoma clinical trial to trial completion [12 months]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Patient has been diagnosed with renal cell carcinoma
-
Patient is a minimum of 18 years or older
-
Patient has self-identified as planning to enroll in a clinical study
Exclusion Criteria:
-
Patient does not understand, sign, and return consent form
-
Inability to perform regular electronic reporting
-
Patient is pregnant
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Power Life Sciences | San Francisco | California | United States | 94107 |
Sponsors and Collaborators
- Power Life Sciences Inc.
Investigators
- Study Director: Michael B Gill, Power Life Sciences Inc.
Study Documents (Full-Text)
More Information
Publications
- Bakouny Z, El Zarif T, Dudani S, Connor Wells J, Gan CL, Donskov F, Shapiro J, Davis ID, Parnis F, Ravi P, Steinharter JA, Agarwal N, Alva A, Wood L, Kapoor A, Ruiz Morales JM, Kollmannsberger C, Beuselinck B, Xie W, Heng DYC, Choueiri TK. Upfront Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors or Targeted Therapy: An Observational Study from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Urol. 2023 Feb;83(2):145-151. doi: 10.1016/j.eururo.2022.10.004. Epub 2022 Oct 20.
- Petejova N, Martinek A. Renal cell carcinoma: Review of etiology, pathophysiology and risk factors. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2016 Jun;160(2):183-94. doi: 10.5507/bp.2015.050. Epub 2015 Nov 3.
- Schmidinger M, Bamias A, Procopio G, Hawkins R, Sanchez AR, Vazquez S, Srihari N, Kalofonos H, Bono P, Pisal CB, Hirschberg Y, Dezzani L, Ahmad Q, Jonasch E; PRINCIPAL Study Group. Prospective Observational Study of Pazopanib in Patients with Advanced Renal Cell Carcinoma (PRINCIPAL Study). Oncologist. 2019 Apr;24(4):491-497. doi: 10.1634/theoncologist.2018-0787. Epub 2019 Mar 13.
- 74504682